title: Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia.
abstract: BACKGROUND
  A variety of surrogate markers for genetic features and outcome have been described in chronic lymphocytic leukemia based on gene expression analyses. Previous studies mostly focused on individual markers and selected disease characteristics, which makes it difficult to estimate the relative value of the novel markers. Therefore, in the present study a comprehensive approach was chosen investigating 18 promising, partly novel expression markers in a well characterized cohort of patients with long clinical follow-up and full genetic information (IGHV status, genomic abnormalities).
  
  
  METHODS
  Expression markers were evaluated using real-time quantitative reverse transcriptase polymerase chain reaction in CD19(+)-purified samples from 151 patients. Multivariate analyses were performed to test the markers' ability to identify patients at genetic risk and as prognostic markers in the context of established prognostic factors.
  
  
  RESULTS
  For individual markers, ZAP70 expression provided the highest rate (81%) of correct assignment of patients at genetic risk (IGHV unmutated, V3-21 usage, 11q- or 17p-), followed by LPL and TCF7 (76% both). The assignment rate was improved to 88% by information from a four-gene combination (ZAP70, TCF7, DMD, ATM). In multivariate analysis of treatment-free survival, IGHV mutation status and expression of ADAM29 were of independent prognostic value besides disease stage. With regards to overall survival, expression of ATM, ADAM29, TCL1, and SEPT10 provided prognostic information in addition to that derived from clinical and genetic factors.
  
  
  CONCLUSIONS
  Gene expression markers are suitable for screening but not as surrogates for the information from genetic risk factors. While many individual markers may be associated with outcome, only a few are of independent prognostic significance. With regard to prognosis estimation, the genetic prognostic factors cannot be replaced by the expression markers.
authors: Department of Internal Medicine III, University of Ulm, Albert-Einstein-Allee 23, 89081 Ulm, Germany.
authors: Dirk
authors: D
authors: Kienle
authors: Axel
authors: A
authors: Benner
authors: Carolin
authors: C
authors: Läufle
authors: Dirk
authors: D
authors: Winkler
authors: Christof
authors: C
authors: Schneider
authors: Andreas
authors: A
authors: Bühler
authors: Thorsten
authors: T
authors: Zenz
authors: Annett
authors: A
authors: Habermann
authors: Ulrich
authors: U
authors: Jäger
authors: Peter
authors: P
authors: Lichter
authors: Riccardo
authors: R
authors: Dalla-Favera
authors: Hartmut
authors: H
authors: Döhner
authors: Stephan
authors: S
authors: Stilgenbauer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000235:genetics; D015331:Cohort Studies; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics*; D005819:Genetic Markers / Q000235:genetics; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D015996:Survival Rate / Q000639:trends
chemical_list: D014408:Biomarkers, Tumor; D005819:Genetic Markers